fbpx Yourgene Health plc - Home
Infectious Disease
Clarigene® RUO
Clarigene® CE-IVD
Clarigene® SARS-CoV-2 CE-IVD
Clarigene® Feature Notes
NIPT
IONA® Nx
Overview
Workflow
Clinical Performance
Clinical Performance Data
Benefits of the IONA® Nx NIPT Workflow
Instruments
IONA® Software
Atlas Workflow Manager
MyNIPT®
Technical Support
Quality and Regulatory
Choose IONA® Nx NIPT Workflow
the IONA® test
Overview
Technology
CE-IVD
Clinical Performance
Results
MyNIPT®
Application Support
FAQs
Choose IONA®
Contact Us
Laboratory Customer Login
Sage™ Prenatal Screen
For Clinical Laboratories
Overview
Technology
Clinical Performance
Results
Choose Sage™
Sage QS 32plex
For Pregnant Women
Advantages of the Sage™ prenatal screen
Overview
Who can have the Sage™ test
Results
For Healthcare Professionals
Overview
Background
Who can have the Sage™ test
Clinical Performance
Results
Clinical Performance
Results
Contact Us
Reproductive Health
Cystic Fibrosis
Cystic Fibrosis Analysis
Choose CF-EU2
Male Infertility
Pregnancy Loss
Rapid Aneuploidy Analysis
QST*R Range
QST*R Feature Notes
Thrombosis Risk Panel
Precision Medicine
Elucigene DPYD
DPYD Overview
DPYD Testing Workflow
Clinical Performance
Choose Elucigene DPYD
Yourgene Flex™
DNA Size Selection / Enrichment
Ranger® Technology
Overview
Why Choose Ranger®
Applications
LightBench®
Overview
Get to the DNA you care about in NIPT
Get to the DNA you care about in Liquid Biopsy
NGS QC
LightBench® Feature Notes
NIMBUS Select
Yourgene® QS250
Resources
Yourgene® SP150

Studies show there is a specific size discrepancy between the cell free DNA that comes off of a tumour versus the cell free DNA that comes off of healthy cells. Using Ranger® Technology gel-size selection, the LightBench® may be used to enhance cfDNA detection. LightBench® using Ranger® Technology can provide a better outcome for patients by reducing sequencing noise to combat false-positive results. New research has shown that the cost of determining genetic conditions through sequencing can be improved through gel size selection that looks to recover cfDNA from non-normal tissues while excluding that from healthy, normal cells.1

Contact one of our sales representatives to request more information.

T1. PLOS Genetics | DOI:10.1371/journal.pgen.1006162 July 18, 2016
LightBench<sup>®</sup>️ with Ranger<sup>®</sup>️ Technology
50x50 spacer
3D Cancer cells and magnifyinhg glass Image